# EDGAR Filing Document

**Accession Number:** 0001660046
**File Stem:** 0001213900-25-095881
**Filing Date:** 2025-10
**Character Count:** 14443
**Document Hash:** 54a222c2e64bf8cd3386301e484e9c63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-095881.hdr.sgml**: 20251003

**ACCESSION NUMBER**: 0001213900-25-095881

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 6

**CONFORMED PERIOD OF REPORT**: 20251003

**FILED AS OF DATE**: 20251003

**DATE AS OF CHANGE**: 20251003

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immuron Ltd
- **CENTRAL INDEX KEY:** 0001660046
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38104
- **FILM NUMBER:** 251372332

**BUSINESS ADDRESS:**
- **STREET 1:** 62 LYGON STREET
- **STREET 2:** LEVEL 3
- **CITY:** CARLTON, VICTORIA
- **STATE:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 03 9824 5254

**MAIL ADDRESS:**
- **STREET 1:** 62 LYGON STREET
- **STREET 2:** LEVEL 3
- **CITY:** CARLTON, VICTORIA
- **STATE:** C3
- **ZIP:** 3053

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of October 2025

Commission File Number: 001-38104

**<u>IMMURON LIMITED</u>**

(Name of Registrant)

**<u>Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</u>**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

As previously disclosed, on July 2, 2024, Immuron Limited (the "Company") entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright") with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, relating to the offering, issuance, and sale of American Depositary Shares (each, an "ADS" and, collectively the "ADSs") representing the Company's ordinary shares that may be issued and sold from time to time.

The Company has determined to increase the amount available for sale under the ATM Agreement, up to an additional aggregate offering price of $2,847,954. These sales, if any, will be made pursuant to the terms of the ATM Agreement. The ADSs will be sold and issued pursuant the Company's shelf Registration Statement on Form F-3 (File No. 333-280667) which was previously declared effective by the Securities and Exchange Commission, and a related prospectus, as supplemented (the "Registration Statement," and along with the Offering Agreement prospectus dated July 19, 2024 and the accompanying base prospectus dated July 19, 2024, the "Prospectus").

The Company is simultaneously herewith filing a supplement ("Current Prospectus Supplement") to supplement and amend, as of October 3, 2025, the Prospectus to increase the maximum aggregate offering price of the Company's ordinary shares that may be offered, issued and sold under the Prospectus, as supplemented and amended by the Current Prospectus Supplement, pursuant to the ATM Agreement with Wainwright to up to approximately $2,847,954 (which does not include $2,068,866 of securities that were sold pursuant to General Instruction I.B.5 of Form F-3 during the 12-calendar month period that ends on and includes the date hereof).

A copy of the legal opinion as to the legality of the $2,607,382 of securities issuable under the ATM Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.

This report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

This report on Form 6-K shall be deemed to be incorporated by reference into the Registration Statement (including any prospectuses forming a part of such Registration Statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** <br> **Number** | **Description** |
| 5.1 | [Opinion of Francis Abourizk Lightowlers](ea026018001ex5-1_immuron.htm) |
| 23.1 | [Consent of Francis Abourizk Lightowlers (included in Exhibit 5.1)](ea026018001ex5-1_immuron.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMMURON LIMITED** | **IMMURON LIMITED** |
| Date: October 3, 2025 | By: | */s/ Phillip Hains* |
|  |  | Phillip Hains |
|  |  | Company Secretary |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

3 October 2025

The Board of Directors

Immuron Limited

Level 3, 62 Lygon Street

Carlton South VIC 3053

Dear Directors

**Form F-3 Registration Statement** 

We act as Australian legal counsel for Immuron Limited ACN 063 114 045, a company incorporated under the laws of the Commonwealth of Australia (**Company**), with respect to an offer for sale of up to $2,847,954 of American Depositary Shares (**Offer**) pursuant to F-3 Prospectus (including any prospectus supplement) registered with the U.S. Securities and Exchange Commission dated July 19, 2024 (**F-3 Prospectus** or **Registration Statement**). The Registration Statement relates to the registration of up to USD$15,000,000 aggregate amount of certain securities of the Company, being ADSs representing ordinary shares, preference shares, warrants and units.

Each of the American Depositary Shares (**ADSs**) are convertible into 40 fully paid ordinary shares in the Company (**Shares**).

**Assumptions in providing our opinion**

As to various questions of fact relevant to this opinion, we have relied on and assumed the accuracy of, without independent verification:

● an online search of the Company on the Australian Securities and Investments Commission records on 3 October 2025 (**ASIC Search**);

● a circular resolution of the Company's Board of Directors, circulated 21 June 2024; and

● circular resolution of the Company's ATM Share Issue Committee, distributed on 29 May 2025, 3 June 2025, 16 July 2025, 17 July 2025 and 18 July 2025; and

● the Company's Constitution (a copy of which was provided to us by the Company).

For the purpose of the opinions set out below, we have also assumed, without independent investigation or verification, that:

&nbsp;&nbsp;&nbsp;&nbsp;(a) there have been no material changes in relation to the Company between our opinion of 2 July 2024 and the date of this letter;

&nbsp;&nbsp;&nbsp;&nbsp;(b) the ATM Share Issue Committee had appropriate authority delegated to it by the Board of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(c) the genuineness of all signatures and the authenticity of all documents, instruments and certificates submitted to us as originals
and the exact conformity with the authentic originals of all documents, instruments and certificates submitted to us as copies or forms
or originals;

&nbsp;&nbsp;&nbsp;&nbsp;(d) that each party to each document has all the requisite power and authority (corporate and otherwise) to execute and deliver and perform
its obligations thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;(e) all matters of internal management required by the constitution of each of the parties to the relevant documents have been duly attended
to (including, without limitation, the holding of properly constituted meetings of the boards of directors of each of those parties and
the passing at those meetings of appropriate resolutions);

![](ex5-1_002.jpg)

![](ex5-1_003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;(f) that any documents which purport to be governed by the law of any jurisdiction other than the federal and state laws of the Commonwealth
of Australia are legal, valid and binding obligations on all of the parties thereto and under the applicable law and that none of the
execution, delivery or performance of any document by any party thereto violates or contravenes or is rendered invalid, not binding or
unenforceable under any applicable law under any jurisdiction other than the federal and state laws of the Commonwealth of Australia;

&nbsp;&nbsp;&nbsp;&nbsp;(g) the Company will not engage in fraudulent or unconscionable conduct or conduct which is misleading or deceptive or which is likely
to mislead or deceive in relation to the issuance or sale of Shares or ADS;

&nbsp;&nbsp;&nbsp;&nbsp;(h) there is no bad faith, fraud, undue influence, coercion or duress or similar conduct on the part of the Company in relation to the
issuance or sale of Shares or ADS under the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;(i) all information provided to us by or on behalf of officers of the Company was true, correct and complete when provided and remains
so at the date of this letter, containing all information required, without us making any separate enquiry or investigation other than
viewing the ASIC Search, in order for us to provide this opinion;

&nbsp;&nbsp;&nbsp;&nbsp;(j) no party has contravened or will contravene any provision of the Australian Corporations Act 2001 (including Chapters 2E, 2J, 6 or
generally sections 1041H or 1043A) (**Corporations Act**) by the issue of the Registration Statement or giving effect to any transaction
in connection with a Registration Statement or undertaking or being involved in a transaction related to or connected with the Registration
Statement or generally in any subsequent dealing in the Shares or ADS issued under the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;(k) the Company will at all times duly comply with all its obligations under the Corporations Act, the ASX Listing Rules and otherwise
required by law;

&nbsp;&nbsp;&nbsp;&nbsp;(l) the Company is and will be able to pay its debts as and when they fall due and is otherwise solvent as at the time the Shares or ADS
are issued or sold;

&nbsp;&nbsp;&nbsp;&nbsp;(m) the ASIC Search we have examined is accurate and that the information disclosed by the search conducted by us is true and complete
and that such information has not since then been altered and that such search did not fail to disclose any information which had been
delivered for registration or filing against the Company's records but which did not appear on the public records at the date of
our search; and

&nbsp;&nbsp;&nbsp;&nbsp;(n) the Company will lodge all requisite notices with the ASX in respect of the contemplated issue of securities under Offer.

**Opinion**

Based upon and subject to the foregoing, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. when
the issue of the Shares has been duly authorised by the Company, and the ordinary shares have been duly issued, sold and delivered in
accordance with the applicable purchase agreement or other similar agreement approved by, or on behalf of, the Comany's Board
of Directors, the Shares will be legally issued, fully paid and non-assessable;

![](ex5-1_003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;2. when
the issue of the preference shares has been duly authorised by the Company, and the preference shares have been duly issued, sold and
delivered in accordance with the applicable definitive purchase agreement or other similar agreement approved by, or on behalf of, the
Company's Board of Directors, the preference shares will be legally issued, fully paid and non-assessable;

&nbsp;&nbsp;&nbsp;&nbsp;3. when
the issue of the warrants has been duly authorised by the Company, and the warrants have been duly executed and delivered against payment,
pursuant to a warrant agreement or agreements duly authorised, executed and delivered by the Company and a warrant agent, the warrants
will be valid and binding obligations of the Company, subject to any applicable laws, rights or equitable principles;

&nbsp;&nbsp;&nbsp;&nbsp;4. when
the issue of the units has been duly authorised by the Company, and the units have been duly issued, sold and delivered pursuant to a
unit agreement or similar approved by, or on behalf of, the Company's Board of Directors, the units will be valid issued and will
entitle the holders thereof to the rights specified in the relevant unit agreement.

For the purpose of this opinion, the term "non-assessable", when used to describe the liability of a person as the registered holder of shares has no clear meaning under the Corporations Act, so we have assumed those words to mean that holders of such shares, having fully paid all amounts due on such shares, are under no personal liability to contribute to the assets and liabilities of the Company in their capacities purely as holders of such shares .

This opinion is limited to the federal and state laws of the Commonwealth of Australia and no opinion or representation is given in respect of the application of any foreign laws to the issue or transfer of the securities or the contents or generally the compliance of the F-3 Prospectus or any other matters under any applicable US laws or regulations.

**Applicability**

This opinion is given as at the date of this letter and we undertake no obligation to advise you of any changes (including but not limited to any subsequently enacted, published or reported laws, regulations or individual decisions) that may occur or come to our attention after the date of this letter which may affect our opinion.

We consent to incorporation by reference of this opinion in the Prospectus and to the reference of this firm under the caption "Legal Matters" therein, and we consent to the filing of this opinion as an exhibit 5.1 to the Company's Report on Form 6-K.

Yours faithfully,

![](ex5-1_004.jpg)